Systematic review and quality assessment of cost effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer;Revisión y valoración sistemática de la calidad del análisis de costo-efectividad de terapias farmacéuticas para cáncer colorrectal avanzado

Annals of Pharmacotherapy

Volumn 47, Issue 4, 2013, Pages 506-518

  Leung, Henry W C ^a   Chan, Agnes L F ^a   Leung, Matthew S H ^b   Lu, Chin Li ^c  

^a MIN SHENG GENERAL HOSPITAL   (Taiwan)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; COCHRANE LIBRARY; COLON METASTASIS; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DATA EXTRACTION; EMBASE; HUMAN; MEDLINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; STUDY DESIGN; SYSTEMATIC REVIEW;

EID: 84876232285     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R152     Document Type: Article

References (61)

1. WHO Media Centre. http://www.who.int/mediacentre/factsheets/fs297/ en/index.html (accessed 2012 Mar 25).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
3. Garcia-Altes, Ondategui-parra S, Neumann PJ, et al. Cross national comparison of technology assessment processes. Int J Technol Assess Health Care 2004;20:300-10.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Lyon, France: International Agency for Research on Cancer, 2010. http://globocan. iarc.fr (accessed 2012 Mar 25).
5. What are the key statistics about colorectal cancer? American Cancer Society. http://webcache.googleusercontent.com/search?q=cache:OCME9F vvvzMJ:www.cancer.org/Cancer/ColonandRectumCancer/Detailed Guide/ colorectal-cancer-key-statistics+colorectal+cancer+is+the+fourth+ most+common+cancer+in+men+and+women,+after+skin,+prostate,+and+ lung+cancer+in+2012&cd=6&hl=zh-TW&ct=clnk&gl=tw (accessed 2012 Jun 15).
6. Taiwan Cancer Registry. http://tcr.cph.ntu.edu.tw/uploadimages/04 Recrum_CA.pdf (accessed 2012 Mar 26).
7. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28.
8. Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract 2011;7(3 suppl):e30s-7s.
9. Machado M, Iskedjian M, Einarson TR. Quality assessment of published health economic analyses from South America. Ann Pharmacother 2006;40:943-9. doi: 10.1345/aph.1G296
10. Drummond MF, Jefferson TO; for the BMJ Working Party. Guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. BMJ 1996;313:275-83.
11. Sanchez LA. Evaluating the quality of published pharmacoeconomic evaluations. Hosp Pharm 1995;30:146-8.
12. Petrou S, Henderson J, Roberts T, Martin M-A. Recent economic evaluations of antenatal screening: a systematic review and critique. J Med Screening 2000;7:59-73.
13. Hill SH, Mitchell A, Henry D. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000;283:2116?21.
14. Jefferson T, Demicheli V. Quality of economic evaluations in health care. BMJ 2002;324:313-4.
15. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature: are they being used correctly? Ann Intern Med 1992;116:238-44.
16. Sregel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness on Health and Medicine. JAMA 1996;276:1339-41.
17. Manning WG Jr. Panel on Cost-effectiveness in Health and Medicine recommendations: identifying costs. J Clin Psychiatry 1999;60(suppl 3):54-6.
18. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11:1-128.
19. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007;96:206-12.
20. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 2007;29:2256-67.
21. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007;43:2487-94.
22. Annemans L, Van Cutsem E, Humblet Y, Van Laethem JL, Bleiberg H. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan-a Belgian analysis. Acta Clin Belg 2007;62:419-25.
23. Norum J. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. J Chemother 2006;18:532-7.
24. Mittmann N, Au HJ, Tu D, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009;101:1182-92.
25. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first-line treatment of metastatic colorectal cancer. Br J Cancer 2002;86:1677-83.
26. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000;11:157-61.
27. Earle CC, Kwok A, Gazelle GS, Fuchs CS. Two schedules of secondline irinotecan for metastatic colon carcinoma. Cancer 2004;101:2533-9.
28. Iveson TJ, Hickish T, Schmitt C, Van Cutsem E. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999;35:1796-804.
29. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 2009;101:12-8.
30. Shiroiwa T, Fukuda T, Tsutani K. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. Int J Clin Oncol 2010;15:256-62
31. Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005;104:1871-84.
32. Tumeh JW, Shenoy PJ, Moore SG, Kauh J, Flowers C. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. Am J Clin Oncol 2009;32:49-55.
33. Aventis Pharma. Submission to the National Institute of Clinical Excellence (NICE) on Campto (irinotecan) for colorectal cancer (advanced)-irinotecan, oxaliplatin and raltitrexed. Industry submission to NICE; 2004. Health Technol Assess 2008;12:79-81.
34. Lloyd-Jones M, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001;5:1-128.
35. Poston G, Benjamin IS, Diamond T, et al. Costs of neoadjuvant chemotherapy and surgery in patients with liver metastases from advanced colorectal cancer. J Med Econ 2001;4:167-77.
36. Nicholls C, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA alone. J Med Econ 2001;4:115-25.
37. Nicholls CJ, Cassidy J, Freemantle N, Harrison M, Carita P. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone. J Med Econ 2001;4:127-35.
38. Sanofi-Synthelabo. The use of oxaliplatin for the treatment of advanced colorectal cancer (review of NICE guidance no. 33). Industry submission to NICE; 2004. Health Technol Assess 2008;12:4-6.
39. Groener MGH. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999;10:283-8.
40. Borget I, Aupérin A, Pignon JP, Abbas M, Bouché O, Mousseau M. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer: results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. Oncology 2006;71:40-8.
41. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
42. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
43. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77:113-9.
44. Douillard JY, Sienna S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME Study. J Clin Oncol 2010;28:4697-705.
45. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [published erratum appears in Lancet 1998;352:1634]. Lancet 1998;352:1407-12.
46. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-14.
47. Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998;16:2943-52.
48. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699-703.
49. Polinder S, Segui-Gomez M, Toet H, et al. Systematic review and quality assessment of economic evaluation studies of injury prevention. Accid Anal Prev 2012;45:211-21.
50. Ruger JP, Emmons KM. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review. Value Health 2008;11:180-90.
51. Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther 2009;31:1279-308.
52. Gerard K. Cost?utility in practice: a policymaker's guide to the state of the art. Health Policy 1992;21:249-79.
53. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomised controlled trials. Med Care 1992;30:231-8.
54. Jefferson T, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 1994;3:25-37.
55. McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force report. Value Health 2009;12:1086-99.
56. Jefferson T, Demicheli V. Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice. Health Econ 1995;4:383-8.
57. Jefferson T, Demicheli V. Quality of economic evaluations in health care. BMJ 2002;324:313-4.
58. Sculpher MJ, Pang FS, Manca A, et. al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004;8:1-192.
59. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000;17:461-77.
60. CONSORT transparent reporting of trials. http://www.consort-statement. org/consort-statement/ (accessed 25 Mar 2012).
61. PRISMA transparent reporting of systematic reviews and meta-analysis http://www.prisma-statement.org/ (accessed 25 Mar 25, 2012).